Search hospitals > Florida > Miami
Veterans Affairs Medical Center -Washington DC
Claim this profileMiami, Florida 33125
Global Leader in Lung Cancer
Global Leader in Head and Neck Cancers
Conducts research for Lymphoma
Conducts research for Squamous Cell Carcinoma
Conducts research for HIV Infection
212 reported clinical trials
12 medical researchers
Summary
Veterans Affairs Medical Center -Washington DC is a medical facility located in Miami, Florida. This center is recognized for care of Lung Cancer, Head and Neck Cancers, Lymphoma, Squamous Cell Carcinoma, HIV Infection and other specialties. Veterans Affairs Medical Center -Washington DC is involved with conducting 212 clinical trials across 354 conditions. There are 12 research doctors associated with this hospital, such as George Kurdgelashvili, MD, Jared M. Gollie, PhD, Anita Aggarwal, and Debra Benator, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Head And Neck Cancers
Global LeaderStage I
Stage II
Stage IV
Top PIs
George Kurdgelashvili, MDOklahoma City VA Medical Center, Oklahoma City, OK7 years of reported clinical research
Studies Diabetes Mellitus
Studies Osteomyelitis
2 reported clinical trials
4 drugs studied
Jared M. Gollie, PhDWashington DC VA Medical Center, Washington, DC2 years of reported clinical research
Studies Fatigue
Studies Coronavirus
2 reported clinical trials
2 drugs studied
Anita AggarwalWashington DC VAMC3 years of reported clinical research
Studies Pulmonary Embolism
Studies Deep Vein Thrombosis
2 reported clinical trials
3 drugs studied
Debra Benator, MDVeterans Affairs Medical Center2 years of reported clinical research
Studies AIDS
Studies HIV/AIDS
2 reported clinical trials
2 drugs studied
Clinical Trials running at Veterans Affairs Medical Center -Washington DC
Prostate Cancer
Pulmonary Embolism
Deep Vein Thrombosis
Fanconi Anemia
HIV/AIDS
Liver Cancer
Multiple Sclerosis
Fatigue
Silent Stroke
Colorectal polyposis syndrome
Pembrolizumab
for Prostate Cancer
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.
Recruiting2 awards Phase 23 criteria
Carboplatin vs Olaparib
for Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Veterans Affairs Medical Center -Washington DC?
Veterans Affairs Medical Center -Washington DC is a medical facility located in Miami, Florida. This center is recognized for care of Lung Cancer, Head and Neck Cancers, Lymphoma, Squamous Cell Carcinoma, HIV Infection and other specialties. Veterans Affairs Medical Center -Washington DC is involved with conducting 212 clinical trials across 354 conditions. There are 12 research doctors associated with this hospital, such as George Kurdgelashvili, MD, Jared M. Gollie, PhD, Anita Aggarwal, and Debra Benator, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.